Alvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva
Alvotech has now entered four biosimilar candidates into confirmatory patient studies
Combined sales of Prolia® and Xgeva® (denosumab) which are used to treat bone diseases were nearly $5.3 billion in 2021
REYKJAVIK, Iceland, Aug. 25,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 25, 2022 Category: Pharmaceuticals Source Type: clinical trials
A Digital Solution for Individuals With Non Alcoholic Fatty Liver Disease
Condition: Non Alcoholic Fatty Liver Disease Intervention: Device: A digital care solution for patients with NAFLD Sponsors: Sidekick Health; Hjartamiðstöðin, Iceland; Hjartavernd, Iceland Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2022 Category: Research Source Type: clinical trials
A Digital Solution for Individuals With Non Alcoholic Fatty Liver Disease
Condition: Non Alcoholic Fatty Liver Disease Intervention: Device: A digital care solution for patients with NAFLD Sponsors: Sidekick Health; Hjartamiðstöðin, Iceland; Hjartavernd, Iceland Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2022 Category: Research Source Type: clinical trials